文献速递膀胱癌与上尿路尿路上皮癌

血液与尿液循环肿瘤DNA在尿路上皮膀胱癌中的应用:现状与临床展望

Blood and Urine Circulating Tumor DNA in Urothelial Bladder Cancer: State of the Art and Clinical Perspective.
PubMed 文献 · Eur Urol Oncol · 2026-03-19

ctDNA与肿瘤组织突变高度一致,术后ctDNA阳性是复发、进展和总生存的独立预测因子,ctDNA清除与对新辅助化疗和免疫检查点抑制剂的反应相关。方法学异质性和小样本队列是主要局限。

要点

  • ctDNA与肿瘤组织突变高度一致,可用于实时监测肿瘤负荷。
  • 根治性膀胱切除术后ctDNA阳性独立预测复发、进展和总生存。
  • ctDNA清除与新辅助化疗和免疫检查点抑制剂治疗反应相关。

核心结论

  • ctDNA是尿路上皮膀胱癌诊断、监测和治疗指导的有力无创生物标志物。
  • 正在进行的III期试验(IMvigor011、TOMBOLA、MODERN)可能确立其作为个体化疾病管理标准工具的临床效用。

研究设计与样本

  • 纳入评估血浆和尿液ctDNA的研究,主要结局包括诊断性能、与组织突变的一致性、疾病监测及预后或预测价值。

主要发现

  • ctDNA与肿瘤组织突变高度一致,对实时监测肿瘤负荷有高度潜力。
  • 在肌层浸润性膀胱癌(MIBC)中的数据比非肌层浸润性膀胱癌(NMIBC)更稳健。
  • 根治性膀胱切除术后ctDNA阳性是复发无生存、进展无生存和总生存的独立预测因子。
  • ctDNA清除与新辅助化疗和免疫检查点抑制剂的反应相关。
  • 在转移性疾病中,高ctDNA突变负荷与较短总生存和耐药机制相关,如PIK3CA介导的成纤维细胞生长因子受体抑制剂耐药。

临床怎么用

  • ctDNA可作为尿路上皮膀胱癌无创诊断、监测和治疗指导的生物标志物。
  • 术后ctDNA阳性提示高复发风险,可能指导辅助治疗决策。
  • ctDNA清除可早期提示新辅助化疗或免疫治疗的反应。

局限性

  • 方法学异质性。
  • 检测灵敏度多变。
  • 患者队列样本量小。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: Urothelial bladder cancer (UBC) carries significant mortality and treatment morbidity. Conventional diagnostic and monitoring methods, including cystoscopy and biopsy, are invasive and limited in sensitivity. Circulating tumor DNA (ctDNA), a minimally-invasive "liquid biopsy," has emerged as a promising tool for real-time disease assessment. This study aimed to systematically evaluate the diagnostic, prognostic, and predictive value of plasma and urine ctDNA in localized, locally advanced, and metastatic UBC. METHODS: A systematic review was conducted according to PRISMA guidelines using PubMed, MEDLINE, and Web of Science databases (January 2016-October 2025). Eligible studies evaluated plasma and urine ctDNA. Main outcomes included diagnostic performance, correlation with tissue mutations, disease monitoring, and prognostic or predictive value. Data synthesis focused on ctDNA detection methods, timing relative to treatment, and survival outcomes. KEY FINDINGS AND LIMITATIONS: ctDNA showed strong concordance with tumor tissue mutations and high potential for real-time monitoring of tumor burden. Data are more robust in muscle-invasive bladder cancer (MIBC) than non-muscle-invasive bladder cancer (NMIBC). Postcystectomy ctDNA positivity was an independent predictor of recurrence-free, progression-free, and overall survival. ctDNA clearance correlated with response to neoadjuvant chemotherapy and immune checkpoint inhibitors. In metastatic disease, high ctDNA mutation burden was associated with shorter overall survival and resistance mechanisms, such as PIK3CA-mediated fibroblast growth factor receptor inhibitor resistance. Limitations included heterogeneous methodologies, variable assay sensitivity, and small patient cohorts. CONCLUSIONS AND CLINICAL IMPLICATIONS: ctDNA represents a powerful non-invasive biomarker for diagnosis, surveillance, and treatment guidance in UBC. Ongoing phase III trials (IMvigor011, TOMBOLA, MODERN) may establish its clinical utility as a standard tool for personalized disease management.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Duquesne I, Epelbaum I, Prost D, et al. Blood and Urine Circulating Tumor DNA in Urothelial Bladder Cancer: State of the Art and Clinical Perspective. Eur Urol Oncol. 2026. PMID: 41862336. doi:10.1016/j.euo.2026.03.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。